JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

NCT07075419 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Refractory Hepatocellular Carcinoma

Interventions

DRUG: JDB153
DRUG: Penpulimab

Sponsor

West China Hospital